Weight loss achieved with newer obesity pharmacotherapies was closely associated with clinically meaningful reductions in systolic blood pressure, according to a meta-analysis presented at the European Congress on Obesity 2026. The analysis suggested that blood pressure reduction closely tracked the magnitude of weight loss achieved during obesity pharmacotherapy.
The meta-analysis included 32 phase 3 clinical trials involving 43,618 adults with overweight or obesity. Marcel Muskiet, David Cherney, and colleagues evaluated placebo-adjusted changes in body weight and blood pressure among adults receiving GLP-1 RAs and multi-hormone receptor modulators, including agents targeting glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, amylin, and glucagon pathways.
The cohort had a mean age of 54 years and a mean body mass index (BMI) of 35.5 kg/m²; 50% of participants were female, and 9.2% had type 2 diabetes mellitus (T2DM). Baseline systolic blood pressure averaged 128 mmHg, and 59% of participants were living with hypertension. Median treatment duration across trials was 66 weeks.
Across all agents and doses, placebo-adjusted mean weight loss reached 10.9%, accompanied by a systolic blood pressure reduction of 5.2 mmHg. Statistical modeling showed that 77% of the variability in blood pressure reduction could be explained by the magnitude of weight loss achieved during treatment. Each 1% reduction in body weight was associated with a 0.34 mmHg reduction in systolic blood pressure. The relationship remained consistent after adjustment for study duration, baseline BMI, sex distribution, and diabetes status, corresponding to a 0.36 mmHg systolic blood pressure reduction per 1% weight loss.
The authors noted that the relationship between obesity pharmacotherapy and blood pressure reduction remains incompletely understood because these therapies may exert both weight-dependent and weight-independent cardiovascular effects. They stated that even in the absence of weight loss, GLP-1–based therapies may influence vascular relaxation, kidney sodium handling, and neurohormonal pathways that contribute to blood pressure regulation.
The authors concluded: “Across phase 3 trials of GLP-1 receptor agonist and multi-hormone receptor modulator obesity drugs in adults with overweight or obesity, the magnitude of blood pressure-lowering was closely associated with the degree of weight loss, highlighting the clinically relevant — yet often underappreciated — BP-lowering potential of these drugs.”
They added that the findings support “a meaningful role for these medications in blood pressure management in overweight and obesity” and emphasized the need for mechanistic and clinical studies to further evaluate weight-dependent and weight-independent effects. Ongoing studies include larger registration trials such as ATTAIN-HYPERTENSION and mechanistic investigations evaluating cardiac, vascular, renal, and neurohormonal effects of obesity pharmacotherapy.
The authors acknowledged several limitations, including the use of trial-level rather than individual patient-level data, variability in trial populations and study design, and the fact that blood pressure was not the primary endpoint in the included trials. They also noted that changes in background antihypertensive therapy may have influenced study findings.
